ICCM Stock Forecast: IceCure Medical Ltd. Price Predictions for 2026-2027
The median 12-month analyst price target for IceCure Medical Ltd. is $29. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores IceCure Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (77): Sales and profits are climbing, and climbing faster than before.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ICCM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ICCM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Maxim Group | Maintains | Buy | $3.00 → $1.00 |
| 7 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2024 | Alliance Global Partners | Maintains | Buy | — |
| 20 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 6 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 15 Aug 2023 | Alliance Global Partners | Maintains | Buy | $4.25 → $4.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ICCM.
This page is one stock. Monday covers all of them.
ICCM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ICCM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, IceCure Medical Ltd. returned −95.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ICCM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.1×
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 63% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 27.9%
- Operating margin
- —
- Net margin
- —
Higher than 31% of US stocks
- Return on equity
- −190.7%
- Return on assets
- −73.4%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IceCure Medical Ltd. has a market value of $4.6M.
Revenue in the twelve months to 30 June 2026: $3.9M. The latest quarter grew 72.8% year on year.
Net income over the same four quarters: −$16.9M, a −427.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$15.9M.
IceCure Medical Ltd. employs 67 people — $59K of revenue per employee.
Data provided by Twelve Data
ICCM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ICCM’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own IceCure Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ICCM
What is the ICCM stock price forecast for 2026-2027?
The median 12-month analyst price target for IceCure Medical Ltd. is $29, with estimates ranging from $28 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ICCM stock a buy right now?
Of the 3 analysts covering IceCure Medical Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IceCure Medical Ltd. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ICCM?
As at 21 Nov 2026, IceCure Medical Ltd. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (77 of 100).
Will ICCM stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $29, and Ticker Nerd's factor model ranks IceCure Medical Ltd. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ICCM stock forecast for 2030?
No analyst covering IceCure Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $30 over the next 12 months.
How has ICCM stock performed over the past year?
IceCure Medical Ltd. returned -95.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IceCure Medical Ltd. do?
IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment. Its core products use liquid nitrogen-based technology to destroy benign and cancerous tumors by freezing them, offering physicians an alternative to traditional surgical removal.
About IceCure Medical Ltd.
IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment. Its core products use liquid nitrogen-based technology to destroy benign and cancerous tumors by freezing them, offering physicians an alternative to traditional surgical removal. The company’s portfolio includes the ProSense system and associated disposable CryoProbes, which are used in procedures across women’s health and interventional oncology. IceCure Medical also supports broader ablation applications in areas such as breast, kidney, bone, and lung cancer, with products designed for use in office-based, operating room, and imaging-guided settings. Based in Caesarea, Israel, IceCure Medical serves healthcare providers in multiple international markets and plays a niche role in expanding access to minimally invasive tumor care.
CEO Mr. Eyal Shamir · 67 employees · Israel · https://www.icecure-medical.com